Peter J. Neumann
Department of Health Policy and Management and Center for Risk Analysis
Harvard School of Public Health
Boston
MA 02115
USA
Name/email consistency: high
- Do drug formulary policies reflect evidence of value? Neumann, P.J., Lin, P.J., Greenberg, D., Berger, M., Teutsch, S., Mansley, E., Weinstein, M.C., Rosen, A.B. Am. J. Manag. Care (2006)
- Medicare's national coverage decisions, 1999-2003: quality of evidence and review times. Neumann, P.J., Divi, N., Beinfeld, M.T., Levine, B.S., Keenan, P.S., Halpern, E.F., Gazelle, G.S. Health. Aff. (Millwood) (2005)
- Growth and quality of the cost-utility literature, 1976-2001. Neumann, P.J., Greenberg, D., Olchanski, N.V., Stone, P.W., Rosen, A.B. Value. Health (2005)
- Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis. Neumann, P.J. Pharmacoeconomics (2005)
- Can we better prioritize resources for cost-utility research?. Neumann, P.J., Rosen, A.B., Greenberg, D., Olchanski, N.V., Pande, R., Chapman, R.H., Stone, P.W., Ondategui-Parra, S., Nadai, J., Siegel, J.E., Weinstein, M.C. Med. Decis. Making (2005)
- Why don't Americans use cost-effectiveness analysis?. Neumann, P.J. Am. J. Manag. Care (2004)
- Economic messages in prescription drug advertisements in medical journals. Neumann, P.J., Zivin Bambauer, K., Ramakrishnan, V., Stewart, K.A., Bell, C.M. Med. Care (2002)
- Do HEDIS measures reflect cost-effective practices?. Neumann, P.J., Levine, B.S. Am. J. Prev. Med (2002)
- Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neumann, P.J., Araki, S.S., Arcelus, A., Longo, A., Papadopoulos, G., Kosik, K.S., Kuntz, K.M., Bhattacharjya, A. Neurology (2001)
- The quality of reporting in published cost-utility analyses, 1976-1997. Neumann, P.J., Stone, P.W., Chapman, R.H., Sandberg, E.A., Bell, C.M. Ann. Intern. Med. (2000)
- Preference-based measures in economic evaluation in health care. Neumann, P.J., Goldie, S.J., Weinstein, M.C. Annu. Rev. Public. Health (2000)
- A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Neumann, P.J., Sandberg, E.A., Araki, S.S., Kuntz, K.M., Feeny, D., Weinstein, M.C. Med. Decis. Making (2000)
- Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neumann, P.J., Hermann, R.C., Kuntz, K.M., Araki, S.S., Duff, S.B., Leon, J., Berenbaum, P.A., Goldman, P.A., Williams, L.W., Weinstein, M.C. Neurology (1999)
- Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Neumann, P.J., Kuntz, K.M., Leon, J., Araki, S.S., Hermann, R.C., Hsu, M.A., Weinstein, M.C. Med. Care (1999)
- Are methods for estimating QALYs in cost-effectiveness analyses improving?. Neumann, P.J., Zinner, D.E., Wright, J.C. Med. Decis. Making (1997)
- Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease. Neumann, P.J., Hermann, R.C., Berenbaum, P.A., Weinstein, M.C. Psychiatr. Serv (1997)